New NIH chief opens up about risky pathogens, postdoc salaries and the year ahead

Max Kozlov

DOI: https://doi.org/10.1038/d41586-024-00086-9

IF: 64.8

2024-01-16

Nature

Abstract:Nature talks to Monica Bertagnolli about hot-button issues and her top priorities for 2024. Nature talks to Monica Bertagnolli about hot-button issues and her top priorities for 2024.

multidisciplinary sciences

What problem does this paper attempt to address?

New NIH director's research agenda spans "the laboratory, the clinic and the community"

Katie Kingwell

DOI: https://doi.org/10.1038/d41573-024-00033-3

IF: 112.288

2024-02-21

Nature Reviews Drug Discovery

Abstract:Monica Bertagnolli, the newly appointed director of the NIH, discusses diversity, inclusion and access to biomedical research. Monica Bertagnolli, the newly appointed director of the NIH, discusses diversity, inclusion and access to biomedical research.

pharmacology & pharmacy,biotechnology & applied microbiology
Once reluctant, new NIH chief Monica Bertagnolli embraces role

Jocelyn Kaiser

DOI: https://doi.org/10.1126/science.adn8381

IF: 56.9

2024-01-05

Science

Abstract:Improving patient care is top priority for head of world's largest biomedical research funder

multidisciplinary sciences
New eyes on the infectious disease prize

Asher Mullard

DOI: https://doi.org/10.1038/d41573-024-00169-2

IF: 112.288

2024-10-15

Nature Reviews Drug Discovery

Abstract:Jeanne Marrazzo, the director of the NIAID, discusses post-COVID pandemic preparedness, H5N1 avian flu and the tension between infectious disease protection versus profit. Jeanne Marrazzo, the director of the NIAID, discusses post-COVID pandemic preparedness, H5N1 avian flu and the tension between infectious disease protection versus profit.

pharmacology & pharmacy,biotechnology & applied microbiology
Major biomedical funder NIH poised for massive reform under Trump 2.0

Max Kozlov

DOI: https://doi.org/10.1038/d41586-024-03736-0

IF: 64.8

2024-11-18

Nature

Abstract:Sweeping changes and more research scrutiny could be on the way for the US National Institutes of Health. Sweeping changes and more research scrutiny could be on the way for the US National Institutes of Health.

multidisciplinary sciences
'I'm not Tony': Anthony Fauci's heir vows new direction at NIAID

Jon Cohen

DOI: https://doi.org/10.1126/science.adp1967

IF: 56.9

2024-03-15

Science

Abstract:Jeanne Marrazzo, an HIV prevention researcher, sees need for more "holistic" approach to community health problems

multidisciplinary sciences
What's Hot This Year in ID Clinical Science

Jeffrey A Freiberg,Patty W Wright

DOI: https://doi.org/10.1093/cid/ciad789

IF: 20.999

2024-01-04

Clinical Infectious Diseases

Abstract:The field of infectious diseases saw numerous exciting advances in 2023. Trials of new antibiotics and treatment regimens sought to address rising rates of antimicrobial resistance. Other studies focused on the most appropriate use of currently available treatments, balancing the dual goals of providing effective treatment and impactful antimicrobial stewardship. Improvements in disease prevention were made through trials of both new vaccines and new chemoprophylaxis approaches. Concerning trends this year included increasing rates of invasive group A streptococcal infections, medical tourism associated cases of fungal meningitis, and the return of locally acquired malaria to the United States. This review covers some of these notable trials and clinical developments in infectious diseases in the past year.

immunology,infectious diseases,microbiology
Trump nominates Jay Bhattacharya to head US National Institutes of Health

Janice Hopkins Tanne

DOI: https://doi.org/10.1136/bmj.q2695

2024-12-03

BMJ

Abstract:President elect Donald Trump said he would nominate Jay Bhattacharya, who opposed lockdowns during the covid-19 pandemic, to head the National Institutes of Health (NIH). Like other Trump nominations he will need confirmation by the Senate to assume his position in January, when Trump takes office.Trump said on social media, "Together, Jay and RFK Jr will restore the NIH to a Gold Standard of Medical Research as they examine the causes of, and solutions to, America's biggest health challenges, including our Crisis of Chronic Illness and Disease."1The NIH is part of the Department of Health and Human Services, which Trump has nominated Robert F Kennedy Jr to head.2 Kennedy is sceptical of vaccines and has indicated he would like to direct NIH to focus on chronic diseases.NIH has a budget of about $48bn (£38bn; €46bn) and supports research through its 27 separate institutes and centres that focus on different diseases....

medicine, general & internal
Challenges and opportunities in 2021

Leila Akkari,Stacey D. Finley,Ping-Chih Ho,Misty Jenkins,Barbara B. Maier,Nicholas McGranahan,Miriam Mutebi,Rushika M. Perera,Carla Daniela Robles-Espinoza,Santosha Vardhana,Liling Wan,Meng Michelle Xu

DOI: https://doi.org/10.1038/s43018-021-00294-6

IF: 22.7

2021-01-01

Nature Cancer

Abstract:Twelve early-career investigators share their thoughts on the challenges faced by their teams and communities during the past year, and look ahead to new opportunities for 2022.
Where are nurse-scientists? Academic nursing research at critical crossroads

Joan R Bloch,Mary Ellen Smith Glasgow

DOI: https://doi.org/10.1016/j.outlook.2022.10.007

Abstract:Background: Academic nursing research is at a critical impasse after the great retirement and resignation during COVID-19. Sustaining and replenishing senior nurse-scientist faculty that are clinical experts with real-world clinical practice is critical. Leveraging the mission of nursing scholarship within the business of building and sustaining externally funded research enterprises in schools of nursing presents conundrums, especially with persistent nursing faculty vacancies. Purpose and methods: Through a lens of intersectionality within the context of academic bias and nursing education regulation, we address challenges in NIH funding for nurse-scientist faculty. Publicly available data reveal equity, inclusion, and advancement issues that make it an unequal playing field for nurse-scientist faculty if expected to achieve similar NIH funding as faculty in schools of public health and medicine. Discussion: Understanding research enterprises requires appreciation of the complex interplay between academic nursing units, university infrastructures, and academic budgetary models. Creative support for both nursing deans and their faculty is needed.
NIH Portfolio Allocation, Lemmings, and the Silent Spring: A Time-Capsule Commentary & Its Update

Mark Boothby

DOI: https://doi.org/10.12688/f1000research.1-5.v1

2012-07-20

Abstract:With the release of the US President's proposed budget for the Federal Fiscal year (FY) 2013, to start October 1, 2012, we've spun yet again into the mad vortex of an appropriation season. Fundamental re-thinks of how biological and medical research are prioritized and funded are urgently needed, but sadly appear to be unlikely unless the research and advocacy communities push harder and in a more unified manner. Early in the Obama presidency and the NIH Directorship of Dr Francis Collins, the FASEB Office of Public Affairs performed an analysis of trends in funding of R01 and other Research Project Grants and shared that with the Director and his office. Using the FASEB analysis, whose numbers drew on NIH data, an independent commentary (below) was submitted to (but not published in) Science. With the analysis a few years old, this older viewpoint is followed by updates that touch on how the trends have fared since early 2010 and comment on other aspects of the ongoing cull in biomedical research. In particular, data on some of the growth areas that continue to prosper at the expense of the ever-declining direct support for R01 science are discussed.
Coronavirus symptoms, research chief quits and Nature’s plan to join Plan S

DOI: https://doi.org/10.1038/d41586-020-01023-2

IF: 64.8

2020-04-15

Nature

Abstract:The president of Europe's most prestigious funding agency has <a href="https://www.nature.com/articles/d41586-020-01075-4">resigned after three months in the post</a> — prompting fiery accusations from the organization's governing body that he largely neglected his responsibilities.

multidisciplinary sciences
Of mice and men, and medicine: an interview with Monica Justice

Monica Justice

DOI: https://doi.org/10.1242/dmm.011809

Abstract:Monica Justice, a recently appointed Senior Editor on Disease Models & Mechanisms (DMM), is Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine (BCM). She leads several research teams that are merging mouse modeling with clinical genetics to elicit new information on disease mechanisms and to develop potential treatment strategies, with a focus on hematopoietic cancers and genetic syndromes. In this interview, Monica discusses what led her to focus on molecular, developmental and translational biology; her current work and future goals; and the reality of creating a balance between a demanding research role and life beyond the lab.
Who Should Be Driving US Science Policy?

Carole R. Baskin

DOI: https://doi.org/10.1353/pbm.2019.0001

2019-01-01

Perspectives in Biology and Medicine

Abstract:Transparency was not always a desired aspect of medicine or STEM (science, technology, engineering, and math) research. In the late 1940s, the Nuremberg Code heralded a new era of informed patient consent, research subject protection, and the view that the public had a stake in emerging technology and should have some knowledge and input into the directions of scientific research. This understanding intensified in the United States with the very public discussions leading to the promulgation of the NIH Guidelines for Recombinant DNA Research in the 1970s. The way in which oversight of recombinant DNA research was handled is still the exception rather than the rule. Starting in the 1990s, various terror incidents led to the enactment of statutes and issuance of regulations that undermined the ability of scientists and research institutions to self-regulate and in some cases to disseminate information freely. This essay explores how the scientific community got to this status quo, and how it could regain some measure of control despite competing needs for transparency and security, so that research critical to biosecurity is supported rather than impeded.

medicine, research & experimental,history & philosophy of science
New Agents Are Coming, and so Is the Resistance

J. Myles Keck,Alina Viteri,Jacob Schultz,Rebecca Fong,Charles Whitman,Madeline Poush,Marlee Martin

DOI: https://doi.org/10.3390/antibiotics13070648

2024-07-14

Antibiotics

Abstract:Antimicrobial resistance is a global threat that requires urgent attention to slow the spread of resistant pathogens. The United States Centers for Disease Control and Prevention (CDC) has emphasized clinician-driven antimicrobial stewardship approaches including the reporting and proper documentation of antimicrobial usage and resistance. Additional efforts have targeted the development of new antimicrobial agents, but narrow profit margins have hindered manufacturers from investing in novel antimicrobials for clinical use and therefore the production of new antibiotics has decreased. In order to combat this, both antimicrobial drug discovery processes and healthcare reimbursement programs must be improved. Without action, this poses a high probability to culminate in a deadly post-antibiotic era. This review will highlight some of the global health challenges faced both today and in the future. Furthermore, the new Infectious Diseases Society of America (IDSA) guidelines for resistant Gram-negative pathogens will be discussed. This includes new antimicrobial agents which have gained or are likely to gain FDA approval. Emphasis will be placed on which human pathogens each of these agents cover, as well as how these new agents could be utilized in clinical practice.

pharmacology & pharmacy,infectious diseases
Terez Shea-Donohue: Optimism helps, and confidence in your work is critical

Montserrat Cols

DOI: https://doi.org/10.1084/jem.20241693

2025-01-06

Abstract:Terez Shea-Donohue is the program director of the Division of Digestive Diseases and Nutrition at the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. As a program director, Terez supports basic and translational research related to neurogastroenterology, gastrointestinal (GI), and GI epithelial barrier function. We spoke to Terez about the transition from active research to a predominantly administrative job, the need for life-long mentorship, and the continued sex/gender bias in health care.
An evaluation of programs to support new investigators at the National Institute of Allergy and Infectious Diseases: Striking a balance with funding for established investigators

Ariel C Zane,James Onken,Marie B Parker,Dolan Ghosh

DOI: https://doi.org/10.1016/j.evalprogplan.2022.102218

Abstract:As the largest funder of basic biomedical research in the US, the National Institutes of Health (NIH) has an interest in maintaining a sustainable, productive workforce of investigators. Over the years, NIH has implemented several programs to attract early-stage investigators and other applicants without prior NIH support. The latest of these is the Next Generation Researchers Initiative. These programs have been shown to be successful in meeting NIH-wide goals but their success for any particular NIH institute or center (IC), and in any particular year, is determined by a variety of factors, some extrinsic to an IC's funding decision process. Each IC must balance support for new investigators with funding for productive ongoing programs of research. We examine historical trends in support of new investigators at the National Institute of Allergy and Infectious Diseases (NIAID) over a 22-year period, as well as trends in some major extrinsic influences on that support. The results indicate that NIH's new investigator programs have succeeded in maintaining a balance between the support for new NIAID investigators while also continuing to support an expanded pool of established investigators. The programs have been particularly effective in providing support to early-stage investigators.
Cuts to high-profile NIH efforts leave researchers reeling

Jocelyn Kaiser

DOI: https://doi.org/10.1126/science.adq1773

IF: 56.9

2024-05-03

Science

Abstract:Drop in 21st Century Cures Act funding will slow BRAIN and All of Us projects

multidisciplinary sciences
US funders to tighten oversight of controversial 'gain-of-function' research

Max Kozlov

DOI: https://doi.org/10.1038/d41586-024-01377-x

IF: 64.8

2024-05-08

Nature

Abstract:New policy on high-risk biology studies aims to address criticism that previous rules were too vague. New policy on high-risk biology studies aims to address criticism that previous rules were too vague.

multidisciplinary sciences
NIH pay rise for postdocs and PhD students could have US ripple effect

Amanda Heidt

DOI: https://doi.org/10.1038/d41586-024-01242-x

IF: 64.8

2024-04-27

Nature

Abstract:Salary increases for the 17,000-plus recipients of an NIH research award could lead to increases in other academic settings. Salary increases for the 17,000-plus recipients of an NIH research award could lead to increases in other academic settings.

multidisciplinary sciences
NIH advisory group pushes for big pay raise for U.S. postdocs

Katie Langin

DOI: https://doi.org/10.1126/science.adn6358

IF: 56.9

2023-12-22

Science

Abstract:Though applauded by many, measure would strain lab budgets if adopted.

New NIH chief opens up about risky pathogens, postdoc salaries and the year ahead

New NIH director's research agenda spans "the laboratory, the clinic and the community"

Once reluctant, new NIH chief Monica Bertagnolli embraces role

New eyes on the infectious disease prize

Major biomedical funder NIH poised for massive reform under Trump 2.0

'I'm not Tony': Anthony Fauci's heir vows new direction at NIAID

What's Hot This Year in ID Clinical Science

Trump nominates Jay Bhattacharya to head US National Institutes of Health

Challenges and opportunities in 2021

Where are nurse-scientists? Academic nursing research at critical crossroads

NIH Portfolio Allocation, Lemmings, and the Silent Spring: A Time-Capsule Commentary & Its Update

Coronavirus symptoms, research chief quits and Nature’s plan to join Plan S

Of mice and men, and medicine: an interview with Monica Justice

Who Should Be Driving US Science Policy?

New Agents Are Coming, and so Is the Resistance

Terez Shea-Donohue: Optimism helps, and confidence in your work is critical

An evaluation of programs to support new investigators at the National Institute of Allergy and Infectious Diseases: Striking a balance with funding for established investigators

Cuts to high-profile NIH efforts leave researchers reeling

US funders to tighten oversight of controversial 'gain-of-function' research

NIH pay rise for postdocs and PhD students could have US ripple effect

NIH advisory group pushes for big pay raise for U.S. postdocs